Citadel Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$470K Sell
8,000
-23,900
-75% -$1M ﹤0.01% 10008
2026
Q1
$1.03M Buy
+31,900
New +$1.18M ﹤0.01% 7600
2025
Q4
Sell
-6,100
Closed -$209K 14162
2025
Q3
$209K Buy
+6,100
New +$175K ﹤0.01% 11175
2025
Q2
Sell
-2,000
Closed -$59.3K 15258
2025
Q1
$59.3K Sell
2,000
-7,800
-80% -$297K ﹤0.01% 12124
2024
Q4
$388K Buy
9,800
+1,900
+24% +$71.9K ﹤0.01% 9120
2024
Q3
$269K Sell
7,900
-15,300
-66% -$430K ﹤0.01% 9552
2024
Q2
$503K Buy
23,200
+14,500
+167% +$305K ﹤0.01% 8035
2024
Q1
$193K Buy
8,700
+1,600
+23% +$39K ﹤0.01% 10377
2023
Q4
$195K Buy
7,100
+2,500
+54% +$60.4K ﹤0.01% 9995
2023
Q3
$103K Sell
4,600
-4,100
-47% -$105K ﹤0.01% 10863
2023
Q2
$222K Sell
8,700
-7,900
-48% -$192K ﹤0.01% 9662
2023
Q1
$370K Buy
16,600
+2,500
+18% +$60.4K ﹤0.01% 8943
2022
Q4
$335K Sell
14,100
-131,000
-90% -$3.04M ﹤0.01% 9079
2022
Q3
$2.41M Buy
145,100
+100
+0.1% +$2.25K ﹤0.01% 5230
2022
Q2
$2.89M Buy
145,000
+126,300
+675% +$2.55M ﹤0.01% 4826
2022
Q1
$516K Buy
18,700
+11,700
+167% +$335K ﹤0.01% 9316
2021
Q4
$288K Buy
7,000
+1,000
+17% +$44.2K ﹤0.01% 11015
2021
Q3
$279K Sell
6,000
-4,600
-43% -$201K ﹤0.01% 11209
2021
Q2
$424K Sell
10,600
-8,200
-44% -$351K ﹤0.01% 10427
2021
Q1
$1.01M Buy
18,800
+10,600
+129% +$611K ﹤0.01% 8084
2020
Q4
$401K Buy
+8,200
New +$380K ﹤0.01% 8566
2019
Q3
Sell
-11,100
Closed -$316K 9787
2019
Q2
$316K Buy
+11,100
New +$277K ﹤0.01% 7513
2018
Q4
Sell
-12,000
Closed -$115K 9801
2018
Q3
$115K Sell
12,000
-1,400
-10% -$15.4K ﹤0.01% 8521
2018
Q2
$125K Buy
+13,400
New +$94.2K ﹤0.01% 8145

Other funds holding VCYT

Citadel Advisors's VCYT Position: Q2 2026 in Review

Citadel Advisors sold out of Veracyte (VCYT) in Q2 2026, closing a stake of 152,941 shares — an estimated $6.41M sold.

Citadel Advisors first reported a position in VCYT in Q4 2015 and held it in 34 quarters. The position peaked at $25.5M in Q1 2023. 371 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Citadel Advisors reported no remaining Veracyte position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 152,941 Veracyte shares in Q2 2026, an estimated $6.41M.
  • Citadel Advisors first reported a position in Veracyte in Q4 2015 and held it in 34 quarters.
  • Citadel Advisors's Veracyte position peaked at $25.5M in Q1 2023.
  • 371 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.